超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析*

doi:10.3969/j.issn.1672-5069.2020.06.008

摘要/Abstract

摘要： 目的研究超声声速匹配联合磁共振弥散加权成像技术评价慢性乙型肝炎(CHB)患者肝纤维化程度的应用价值。方法 2017年2月～2020年2月我院收治的78例CHB患者,均采用超声声速匹配技术计算区域速度指数,并使用磁共振弥散加权成像技术测量表观弥散系数(ADC)。行肝活检,经病理学检查将纤维化程度分为汇管区纤维化(S₁)、汇管区周围纤维化(S₂)、纤维间隔形成伴小叶结构紊乱(S₃)和肝硬化(S₄)四期,比较不同分期肝纤维化患者ADC值和区域速度指数的差异。采用受试者工作特征曲线(ROC)分析ADC、区域速度指数或两者联合判断肝纤维化程度的价值。结果经组织病理学检查,在78例CHB患者中,发现S₁期20例,S₂期18例,S₃期24例和S₄期16例;S₁期患者区域速度指数为(21.7±5.9)m/s,显著低于S₂期【(26.8±7.3)m/s,P<0.05】、S₃期【(33.5±8.1)m/s,P<0.05】或S₄期【(36.0±9.2)m/s,P<0.05】;S₁期患者ADC值为(1.3±0.2)×10^-3mm²/s,显著高于S₂期【(1.2±0.2)×10^-3mm²/s,P<0.05】、S₃期【(1.1±0.1)×10^-3mm²/s,P<0.05)】或S₄期【(0.9±0.1)×10^-3mm²/s,P<0.05】;ROC分析显示区域速度指数判断S₄期肝纤维化的曲线下面积(AUC)为0.724(95%CI=0.597～0.851),其诊断>S₂期肝纤维化的敏感度为0.750,特异度为0.532。ADC值判断>S₂期肝纤维化AUC为0.715(95%CI=0.569～0.861),其敏感度为0.758,特异度为0.625。两者联合判断>S₂期肝纤维化AUC为0.809(95%CI=0.678～0.910),其敏感度为0.813,特异度为0.710。区域速度指数与ADC值联合判断>S₂期肝纤维化AUC显著高于任何一项检测(P<0.05)。结论 CHB患者定期接受超声声速匹配和磁共振弥散加权成像检查可动态监测肝纤维化程度,可指导临床早期作出合理的病情判断,值得进一步研究。

关键词: 慢性乙型肝炎, 超声声速匹配, 磁共振弥散加权成像, 肝纤维化, 诊断

Abstract: Objective The purpose of this study was to investigate the diagnostic value of ultrasonic velocity matching and MR diffusion imaging in evaluating liver fibrosis in patients with chronic hepatitis B (CHB). Methods 78 patients with CHB were admitted in our hospital between February 2017 and February 2020, and all received ultrasonic velocity matching check-up for regional velocity index and MR diffusion imaging for apparent diffusion coefficient (ADC) measurement. The liver biopsies were performed in all patients and the liver fibrosis were divided into four stages, e.g. portal area fibrosis for S₁, fibrosis around the portal area for S₂, fibrous septum formation with lobular structure disorder for S₃ and early liver cirrhosis for S₄. The ADC value and regional velocity index were compared in different stages. The diagnostic value of ADC and regional velocity index and their combination in judging liver fibrosis were analyzed by receiver operating characteristic curve (ROC). Results There were 20 cases of S₁ stage, 18 cases of S₂ stage, 24 cases of S₃ stage and 16 cases of S₄ stages in our 78 patients after histopathological examination; the regional velocity index in patients with S₁ was (21.7±5.9) m/s, which was significantly lower than 【(26.8±7.3) m/s, P<0.05】 in patients with S₂, or 【(33.5±8.1) m/s, P<0.05】 in patients with S₃ or 【(36.0±9.2) m/s, P<0.05】 in those with S₄; there were significant differences in regional velocity index among four groups of different stages of liver fibrosis(P<0.05); the ADC value in patients with S₁ was (1.3±0.2)× 10^-3mm²/s, which was significantly higher than 【(1.2±0.2)×10^-3mm²/s, P<0.05】 in patients with S₂, or 【(1.1±0.1)×10^-3mm²/s, P<0.05)】 in patients with S₃ or 【(0.9±0.1)×10^-3mm²/s, P<0.05】 in patients with S₄; there were significant difference in ADC among the four groups of different stages of liver fibrosis (P<0.05); the ROC analysis showed that the area under the curve (AUC)of regional velocity index in judging >S₂ stage of liver fibrosis was 0.724 (95%CI=0.597-0.851),with the sensitivity and specificity of 0.750 and 0.532, respectively, and the AUC of ADC in judging >S₂ stage of liver fibrosis was 0.715 (95%CI=0.569-0.861), with the sensitivity of 0.758 and the specificity of 0.625, whereas the AUC of the two combination in judging >S₂ stage of liver fibrosis was 0.809 (95%CI=0.678-0.910), with the sensitivity of 0.813 and the specificity of 0.710; the AUC of the combination of the two parameters in judging >S₂ stage of liver fibrosis in patients with chronic hepatitis B was significantly higher than those by any of the two examination alone (P<0.05). Conclusion It is practical to evaluate the liver fibrosis staging or the early screening of liver cirrhosis by ultrasonic velocity matching and MR diffusion imaging, and the dynamic monitoring of liver fibrosis by the regional velocity index and ADC value even helpful.

Key words: Hepatitis B, Ultrasonography, Ultrasonic velocity matching, MR diffusion imaging, Diagnosis

韩冬, 陆洋, 柏根基, 史昭菲. 超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 789-792.

Han Dong, Lu Yang, Bai Genji, et al. Diagnostic value of ultrasonic velocity matching and MR diffusion imaging in evaluating liver fibrosis in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2020, 23(6): 789-792.

参考文献

[1] Mousa N, Abdel RA, Sheta T, et al. Serum leptin and homeostasis model assessment-IR as novel predictors of early liver fibrosis in chronic hepatitis B virus infection. Br J Biomed Sci, 2018, 75(4):192-196.
[2] Ma H, Mak L, Cheung K, et al. Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naive chronic hepatitis B with low viral loads: results from a matched case-control study. J Hepatol, 2019, 70(1):264-268.
[3] Sobhy A, Mohammed FM , Azeem HA , et al. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. J Invest Med, 2019, 67(3):681-685.
[4] Ladouceur M, Baron S, Antoine VN, et al. Role of myocardial collagen degradation and fibrosis in right ventricle dysfunction in transposition of the great arteries after atrial switch. Int J Cardiol, 2018, 258(7):83-89.
[5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年). 中华肝脏病杂志, 2019, 27(9):657-667.
[6] Duman DG, Zibandeh N , Ugurlu MU , et al. Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. Mol Biol Rep, 2019, 46(3):2997-3008.
[7] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[8] Melgar LP, Luquero A, Parra RM, et al. Graphene-dendrimer nanostars for targeted macrophage overexpression of metalloproteinase 9 and hepatic fibrosis precision therapy. Nano Lett, 2018, 18(9):5839-5845.
[9] 闫瑞斌, 马淑梅, 卓玛, 等.慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨. 实用肝脏病杂志, 2019, 22(4):506-510.
[10] Lebda MA, Sadek KM,Abouzed TK , et al. Melatonin mitigates thioacetamide-induced hepatic fibrosis via antioxidant activity and modulation of proinflammatory cytokines and fibrogenic genes. Life Sci, 2018, 192(17):136-143.
[11] Yue JY, Sun YY, Xu J, et al. Cucurbitane triterpenoids from the fruit of momordica charantia L. and their anti-hepatic fibrosis and anti-hepatoma activities. Phytochemistry, 2019, 157(2):21-27.
[12] Kharat PB, More SD, Somvanshi SB, et al. Exploration of thermoacoustics behavior of water based nickel ferrite nanofluids by ultrasonic velocity method. J Mater Sci, 2019, 30(7):6564-6574.
[13] Li DQ, Wei JX, Di BR, et al. Experimental study and theoretical interpretation of saturation effect on ultrasonic velocity in tight sandstones under different pressure conditions. Geophys J Int, 2017, 212(3):2226-2237.
[14] 唐卫平, 胡琦, 戴小明, 等. 脂肪间充质干细胞移植对肝纤维化的治疗作用及其机制.中华肝脏病杂志, 2018, 26(1):28-33.
[15] Keller S, Sedlacik J, Schuler T, et al. Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis. Eur Radiol, 2018, 29(2):818-828.
[16] Pozzi G, Albano D, Messina C, et al. Solid bone tumors of the spine: Diagnostic performance of apparent diffusion coefficient measured using diffusion eighted MRI using histology as a reference standard. J Magn ResonImaging, 2018,47(3):1034-0142.
[17] Ge M, Liu H, Zhang Y, et al. The anti-hepatic fibrosis effects of dihydrotanshinone I are mediated by disrupting the yes-associated protein and transcriptional enhancer factor D₂ complex and stimulating autophagy. Br J Pharmacol, 2017, 174(10):1147-1160.
[18] Li F, Yan HH, Wang JY, et al. Non-invasively differentiating extent of liver fibrosis by visualizing hepatic integrinαvβ3 expression with an MRI modality in mice. Biomaterials, 2016,102(9):162-174.
[19] Soylu A, Kilickesmez O, Poturoglu S, et al. Utility of diffusion-weigh-ted MRI for assessing liver fibrosis inpatients with chronic active hepatits. Diagn Interv Radiol, 2010, 16(3):204-208.
[20] Lee Y , Kim H . Assessment of diffusion tensor MR imaging (DTI) in liver fibrosis with minimal confounding effect of hepatic steatosis. Magn Reson Med, 2015, 73(4):1602-1608.
[21] Taouli B, Chouli M, Martin AJ, et al. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging, 2008, 28(1):89-95.

超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析^*

Diagnostic value of ultrasonic velocity matching and MR diffusion imaging in evaluating liver fibrosis in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[2]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[3]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[4]	夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高. 非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 43-46.
[5]	宋金云, 王建芳, 赵宏宇. 慢性乙型肝炎和肝硬化患者血清HBV基因型分析[J]. 实用肝脏病杂志, 2021, 24(1): 87-90.
[6]	张昕, 郭悦, 杨军. 瞬时弹性成像测定肝脾硬度值评估乙型肝炎肝硬化患者食管静脉曲张初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 95-98.
[7]	刘瑞清(综述), 袁小澎(审校). 缺氧诱导因子-1α参与肝纤维化形成机制研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 145-148.
[8]	宋叶雨(综述), 范建高(审校). 少肌性肥胖合并脂肪性肝病的诊断与治疗[J]. 实用肝脏病杂志, 2021, 24(1): 149-152.
[9]	詹爱琴, 陈春丽, 朱庆峰, 李冰洁, 左维泽, 卢丽君. 异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 793-796.
[10]	柳迪, 董鑫, 杨建军, 吴云英, 张龙方, 刘妍. 瞬时弹性成像联合门静脉血流动力学指标诊断慢性乙型肝炎患者肝纤维化意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(6): 797-800.
[11]	唐平阳, 王洁冰, 张晓兰, 唐启群. 血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 801-804.
[12]	崔璐瑶, 苑喜微, 刘领弟, 张莹, 赵文, 赵丹丹, 杨杨, 南月敏. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 809-812.
[13]	李萍英, 李娟, 谢守珍, 杨永耿, 陆伦根. FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 817-820.
[14]	孙浩, 朱桂娟, 陈小宇. 多层螺旋CT测定全肝体积/脾脏体积比对诊断肝硬化的价值研究[J]. 实用肝脏病杂志, 2020, 23(6): 837-840.
[15]	宋丽俊, 鲁雪红, 薛志伟, 张梅, 王伟. CT血管三维重建鉴别布加综合征与乙型肝炎肝硬化价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 865-868.